CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 78 enrolled
Drug / intervention
Norepinephrine +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05506319
NCT05506319Phase 4Completed
CompareCT.gov

Incidence of Hypotension in the Weaning From Vasopressor Drugs

Hospital Nossa Senhora da Conceicao·interventional·Posted Aug 18, 2022·Updated Mar 14, 2025

In Brief

A Phase 4 clinical trial evaluating Norepinephrine and Vasopressin for Septic Shock. Completed, enrolled 78 participants across 1 site.

Detailed Summary

Although there is consensus in the literature on hemodynamic management of septic shock in the resuscitation phase, the best way to conduct the weaning of vasopressor drugs in the stabilization phase remains open. The present study aims to study the incidence of hypotension in the weaning phase of vasopressor drugs- norepinephrine and vasopressin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeptic Shock
CountriesBrazil
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedAug 18, 2022
Enrollment StartMay 1, 2022
Primary CompletionDec 1, 2022
Study CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.9 years ago

Interventions

Norepinephrineother

The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).

Vasopressinother

The patients will be randomized for the initial suspension of vasopressin (vasopressin group).